|
1
|
de Martel C, Ferlay J, Franceschi S,
Vignat J, Bray F, Forman D and Plummer M: Global burden of cancers
attributable to infections in 2008: A review and synthetic
analysis. Lancet Oncol. 13:607–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Oliveras-Ferraros C, Vazquez-Martin A,
Cufí S, Torres-Garcia VZ, Sauri-Nadal T, Barco SD, Lopez-Bonet E,
Brunet J, Martin-Castillo B and Menendez JA: Inhibitor of Apoptosis
(IAP) survivin is indispensable for survival of HER2 gene-amplified
breast cancer cells with primary resistance to HER1/2-targeted
therapies. Biochem Biophys Res Commun. 407:412–419. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Regan MM, Neven P, Giobbie-Hurder A,
Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I,
Wardley A, et al: Assessment of letrozole and tamoxifen alone and
in sequence for postmenopausal women with steroid hormone
receptor-positive breast cancer: The BIG 1–98 randomised clinical
trial at 8.1 years median follow-up. Lancet Oncol. 12:1101–1108.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bliss JM, Kilburn LS, Coleman RE, Forbes
JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J,
Paridaens R, et al: Disease-related outcomes with long-term
follow-up: An updated analysis of the intergroup exemestane study.
J Clin Oncol. 30:709–717. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davies C, Pan H, Godwin J, Gray R,
Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A,
Bonfill X, et al: Long-term effects of continuing adjuvant
tamoxifen to 10 years versus stopping at 5 years after diagnosis of
oestrogen receptor-positive Breast cancer: ATLAS, a randomised
trial. Lancet. 381:805–816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burstein HJ, Temin S, Anderson H, Buchholz
TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky
AJ, et al: Adjuvant endocrine therapy for women with hormone
receptor-positive breast cancer: American society of clinical
oncology clinical practice guideline focused update. J Clin Oncol.
32:2255–2269. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Traub F, Feist H, Kreipe HH and Pich A:
SELDI-MS-based expression profiling of ductal invasive and lobular
invasive human Breast carcinomas. Patholo Res Pract. 201:763–770.
2005. View Article : Google Scholar
|
|
8
|
Caldon CE, Sergio CM, Kang J,
Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black
MA, Miller LD, et al: Cyclin E2 overexpression is associated with
endocrine resistance but not insensitivity to CDK2 inhibition in
human Breast cancer cells. Mol Cancer Ther. 11:1488–1499. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Osborne CK and Schiff R: Mechanisms of
endocrine resistance in breast cancer. Annu Rev Med. 62:233–247.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garcia-Becerra R, Santos N, Diaz L and
Camacho J: Mechanisms of resistance to endocrine therapy in breast
cancer: Focus on signaling pathways, miRNAs and genetically based
resistance. Int J Mol Sci. 14:108–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
O'Hara J, Vareslija D, McBryan J, Bane F,
Tibbitts P, Byrne C, Conroy RM, Hao Y, Gaora PÓ, Hill AD, et al:
AIB1: ERα transcriptional activity is selectively enhanced in
aromatase inhibitor-resistant breast cancer cells. Clin Cancer Res.
18:3305–3315. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hawsawi Y, El-Gendy R, Twelves C, Speirs V
and Beattie J: Insulin-like growth factor-oestradiol crosstalk and
mammary gland tumourigenesis. Biochim Biophys Acta. 1836:345–353.
2013.PubMed/NCBI
|
|
13
|
Hasson SP, Rubinek T, Ryvo L and Wolf I:
Endocrine resistance in breast cancer: Focus on the
phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin
signaling pathway. Breast Care (Basel). 8:248–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rao X, Di Leva G, Li M, Fang F, Devlin C,
Hartman-Frey C, Burow ME, Ivan M, Croce CM and Nephew KP:
MicroRNA-221/222 confers breast cancer fulvestrant resistance by
regulating multiple signaling pathways. Oncogene. 30:1082–1097.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ward A, Shukla K, Balwierz A, König R,
Sahin O and Wiemann S: MicroRNA-519a is a novel oncomir conferring
tamoxifen resistance by targeting a network of tumour-suppressor
genes in ER+ breast cancer. J Pathol. 233:368–379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zelnak AB and O'Regan RM: Optimizing
endocrine therapy for breast cancer. J Natl Compr Canc Netw.
13:e56–64. 2015.PubMed/NCBI
|
|
17
|
Regan MM: Predicting benefit of endocrine
therapy for early breast cancer. Breast S0960–9776. 00167–00168.
2015.
|
|
18
|
Feng Q, Zhang Z, Shea MJ, Creighton CJ,
Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, et al: An
epigenomic approach to therapy for tamoxifen-resistant breast
cancer. Cell Res. 24:809–819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goss PE, Ingle JN, Martino S, Robert NJ,
Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard
KI, et al: National Cancer Institute of Canada Clinical Trials
Group MA.17: Efficacy of letrozole extended adjuvant therapy
according to estrogen receptor and progesterone receptor status of
the primary tumor: National Cancer Institute of Canada Clinical
Trials Group MA.17. J Clin Oncol. 25:2006–2011. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arpino G, Weiss H, Lee AV, Schiff R, De
Placido S, Osborne CK and Elledge RM: Estrogen receptor-positive,
progesterone receptor-negative breast cancer: Association with
growth factor receptor expression and tamoxifen resistance. J Natl
Cancer Inst. 97:1254–1261. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Richer JK, Jacobsen BM, Manning NG, Abel
MG, Wolf DM and Horwitz KB: Differential gene regulation by the two
progesterone receptor isoforms in human breast cancer cells. J Biol
Chem. 277:5209–5218. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nicholson RI and Johnston SR: Endocrine
therapy-current benefits and limitations. Breast Cancer Res Treat.
93:S3–10. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wright C, Nicholson S, Angus B, et al:
Relationship between c-erbB-2 protein product expression and
response to endocrine therapy in advanced breast cancer. Br J
Cancer. 65:118–121. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meng S, Tripathy D, Shete S, Ashfaq R,
Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, et al:
HER-2 gene amplification can be acquired as breast cancer
progresses. Proc Natl Acad Sci USA. 101:9393–9398. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gregory RK, Powles TJ, Salter J, Chang JC,
Ashley S and Dowsett M: Prognostic relevance of cerbB2 expression
following neoadjuvant chemotherapy in patients in a randomised
trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast
Cancer Res Treat. 59:171–175. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fan P, Yue W, Wang JP, Aiyar S, Li Y, Kim
TH and Santen RJ: Mechanisms of resistance to structurally diverse
antiestrogens differ under premenopausal and postmenopausal
conditions: Evidence from in vitro breast cancer cell models.
Endocrinology. 150:2036–2045. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bliss JMI, Kilburn LS, Coleman RE, Forbes
JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J,
Paridaens R, et al: Disease-related outcomes with long-term
follow-up: An updated analysis of the intergroup exemestane study.
J Clin Oncol. 30:709–717. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van de Velde CJ, Rea D, Seynaeve C, Putter
H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y,
Hille ET, et al: Adjuvant tamoxifen and exemestane in early breast
cancer (TEAM): a randomised phase 3 trial. Lancet. 377:321–331.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jha K, Shukla M and Pandey M: Survivin
expression and targeting in breast cancer. Surg Oncol. 21:125–131.
2012. View Article : Google Scholar : PubMed/NCBI
|
